Key result
Bivalent RSV vaccine efficacy for heart failure and RSV hospitalizations remains unquantified.
Why the study?
Does a Bivalent RSV Prefusion F Protein-Based Vaccine prevent RSV and heart failure hospitalizations in older adults?
RCT
Does a Bivalent RSV Prefusion F Protein-Based Vaccine prevent RSV and heart failure hospitalizations in older adults?
Answers are grounded in this paper and cite their sources.
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Older Adults (DAN-RSV; NCT06684743).The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate.For more information, visit the Author Center.
No takes yet. Share an insight, caveat, or question.
Skaarup et al. (2025) conducted an RCT in Heart Failure and RSV. Bivalent RSV Prefusion F Protein-Based Vaccine was evaluated on RSV Hospitalizations and Heart Failure Hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: